| Coronary heart disease

Xarelto vs Caduet

Side-by-side clinical, coverage, and cost comparison for coronary heart disease.

Deep comparison between: Xarelto vs Caduet with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsCaduet has a higher rate of injection site reactions vs Xarelto based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Caduet but not Xarelto, including UnitedHealthcare

Category

Xarelto

Caduet

At A Glance

RouteOral

FrequencyOnce or twice daily

ClassFactor Xa inhibitor

RouteOral

FrequencyDaily

ClassCalcium channel blocker + HMG-CoA reductase inhibitor

Indications

Atrial Fibrillation
Deep Vein Thrombosis
Pulmonary Embolism
Venous Thrombosis
Coronary heart disease
Peripheral Arterial Diseases

Hypertensive disease
Stable angina
Angina Pectoris, Variant
Coronary Artery Disease
Hyperlipidemia
Heterozygous familial hypercholesterolemia [HeFH]
Homozygous familial hypercholesterolemia [HoFH]
Hyperlipoproteinemia Type III
Hypertriglyceridemia
Diabetes Mellitus, Non-Insulin-Dependent
Coronary heart disease

Dosing

Atrial Fibrillation 20 mg once daily with evening meal (CrCl >50 mL/min); 15 mg once daily with evening meal (CrCl <=50 mL/min), oral.

Deep Vein Thrombosis, Pulmonary Embolism 15 mg twice daily with food for 21 days, then 20 mg once daily with food for remaining treatment, oral.

Venous Thrombosis 10 mg once daily with or without food: for recurrence prevention after at least 6 months of standard anticoagulant treatment; or 35 days post-hip replacement surgery; or 12 days post-knee replacement surgery; or 31-39 days total for prophylaxis in acutely ill medical patients, oral.

Coronary heart disease, Peripheral Arterial Diseases 2.5 mg twice daily with or without food, in combination with aspirin 75-100 mg once daily, oral.

Hypertensive disease Amlodipine 5 mg orally once daily (initial); max 10 mg once daily; start at 2.5 mg in elderly, fragile, small adult, pediatric (>6 years), or patients with hepatic insufficiency.

Stable angina, Angina Pectoris, Variant Amlodipine 5-10 mg orally once daily; most patients require 10 mg for adequate effect.

Coronary Artery Disease Amlodipine 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.

Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia, Diabetes Mellitus, Non-Insulin-Dependent, Coronary heart disease Atorvastatin 10-80 mg orally once daily; start at 40 mg if LDL-C reduction >45% is required.

Heterozygous familial hypercholesterolemia [HeFH] Atorvastatin 10-80 mg orally once daily in adults; 10-20 mg once daily in pediatric patients >=10 years.

Homozygous familial hypercholesterolemia [HoFH] Atorvastatin 10-80 mg orally once daily in adults and pediatric patients >=10 years; starting dose 10-20 mg once daily.

Contraindications

Active pathological bleeding
Severe hypersensitivity reaction to rivaroxaban or any excipient (e.g., anaphylactic reactions)

Acute liver failure or decompensated cirrhosis
Hypersensitivity to amlodipine, atorvastatin, or any excipient in CADUET, including reactions such as anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Drug Interactions

1272View drug interactions

2190View drug interactions

Adverse Reactions

Most common Bleeding complications, wound secretion, pruritus, back pain, abdominal pain, muscle spasm, dizziness, fatigue

Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding, spinal/epidural hematoma

Postmarketing Agranulocytosis, thrombocytopenia, jaundice, cholestasis, hepatitis, hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema, hemiparesis, anticoagulant-related nephropathy, eosinophilic pneumonia, Stevens-Johnson syndrome, DRESS, atraumatic splenic rupture

Most common Edema, dizziness, flushing, palpitations, nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain

Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose

Postmarketing Rhabdomyolysis, myositis, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, gynecomastia

Pharmacology

Rivaroxaban is a selective oral Factor Xa (FXa) inhibitor that does not require a cofactor for activity; by inhibiting free FXa and prothrombinase activity, it decreases thrombin generation and indirectly inhibits thrombin-induced platelet aggregation.

CADUET combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance and blood pressure, with atorvastatin, a selective, competitive HMG-CoA reductase inhibitor that lowers plasma cholesterol by reducing cholesterol synthesis in the liver and increasing hepatic LDL receptor expression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Xarelto